SGMO - Sangamo Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
9.63
+0.25 (+2.67%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close9.38
Open9.45
Bid9.52 x 4000
Ask9.70 x 3100
Day's Range9.30 - 9.69
52 Week Range4.81 - 13.33
Volume1,366,970
Avg. Volume2,328,596
Market Cap1.357B
Beta (5Y Monthly)2.23
PE Ratio (TTM)N/A
EPS (TTM)-0.83
Earnings DateAug 05, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Sangamo Announces R&D Organization Changes
    Business Wire

    Sangamo Announces R&D Organization Changes

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization.

  • Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)
    Insider Monkey

    Hedge Funds Are Getting Crazy About Sangamo Therapeutics, Inc. (SGMO)

    The financial regulations require hedge funds and wealthy investors that exceeded the $100 million equity holdings threshold to file a report that shows their positions at the end of every quarter. Even though it isn't the intention, these filings to a certain extent level the playing field for ordinary investors. The latest round of 13F […]

  • Pfizer's hemophilia gene therapy shows sustained effect in early-stage study
    Reuters

    Pfizer's hemophilia gene therapy shows sustained effect in early-stage study

    All five patients in an early-stage trial given the one-time treatment, giroctocogene fitelparvovec, did not have spontaneous bleeding episodes or require infusions of the blood-clotting protein they otherwise lack, the companies said. Pfizer and Sangamo's therapy is one of several treatments being developed for hemophilia A, as an alternative to the current practice that requires regular infusions to replace the missing protein, factor VIII. On Wednesday, a rival gene therapy by BioMarin Pharmaceutical Inc was found to reduce bleeding episodes by over 90% in patients treated four years ago.

  • Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
    Business Wire

    Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy

    Pfizer Inc. (NYSE:PFE) and Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec (SB-525, or PF-07055480), an investigational gene therapy for patients with severe hemophilia A. All five patients with severe hemophilia A who received the 3e13 vg/kg dose showed sustained factor VIII (FVIII) activity levels, with a median of 64.2% via chromogenic assay (patient-level geometric means after week 9 post-infusion). No patients experienced bleeding events or required FVIII infusions. The factor VIII activity levels reflect measurements up to 61 weeks, the extent of follow-up for the longest-treated patient in the cohort. These data are being presented today as a late-breaking oral abstract at the World Federation of Hemophilia 2020 World Congress, which is being held virtually from June 14 to June 19, 2020.

  • Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?
    Zacks

    Are Options Traders Betting on a Big Move in Sangamo (SGMO) Stock?

    Investors need to pay close attention to Sangamo (SGMO) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents

    Edited Transcript of SGMO.OQ earnings conference call or presentation 11-May-20 9:00pm GMT

    Q1 2020 Sangamo Therapeutics Inc Earnings Call

  • Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics
    Motley Fool

    Better Buy: CRISPR Therapeutics vs. Sangamo Therapeutics

    CRISPR Therapeutics (NASDAQ: CRSP) and Sangamo Therapeutics (NASDAQ: SGMO) are clinical-stage biotech companies aiming to capture a slice of the cell and gene therapy market, which will grow to be $12 billion in size by 2025. As gene therapy companies, both have developed technology platforms that make it possible to alter the genome and therefore change the behavior of a patient's cells. Any investor would benefit from learning about these biotech companies and the exciting world of gene editing.

  • Sangamo Stock Avoids Biotech Pitfall On Pfizer-Partnered Gene Therapy
    Investor's Business Daily

    Sangamo Stock Avoids Biotech Pitfall On Pfizer-Partnered Gene Therapy

    Shares of Sangamo Therapeutics surged Thursday ahead of an update next week for its Pfizer-partnered gene therapy in hemophilia A. SGMO stock popped in high volume.

  • Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference
    Business Wire

    Sangamo Therapeutics Announces Participation at the Jefferies Virtual Healthcare Conference

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET.

  • Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference
    Business Wire

    Sangamo Therapeutics Announces Participation at the Bank of America 2020 Health Care Conference

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Bank of America 2020 Health Care Conference on Thursday, May 14 at 4:20 p.m. ET.

  • Sangamo Therapeutics Inc (SGMO) Q1 2020 Earnings Call Transcript
    Motley Fool

    Sangamo Therapeutics Inc (SGMO) Q1 2020 Earnings Call Transcript

    With me this afternoon on this call are several members of the Sangamo senior management team, including Sandy Macrae, Chief Executive Officer; Sung Lee, Chief Financial Officer; Stephane Boissel, Head of Corporate Strategy; Adrian Woolfson, Head of Research and Development; Mark McClung, Chief Business Officer; and Bettina Cockroft, Chief Medical Officer. Slides from our corporate presentation can be found in our website sangamo.com under the Investors and Media section in the Events and Presentations page.

  • Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
    Zacks

    Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates

    Sangamo (SGMO) delivered earnings and revenue surprises of -60.87% and -57.78%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results
    Business Wire

    Sangamo Therapeutics Reports Business Highlights and First Quarter 2020 Financial Results

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported first quarter 2020 financial results and recent business highlights.

  • Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting
    Business Wire

    Sangamo Therapeutics Announces Virtual Format for 2020 Annual Meeting

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that it is changing its 2020 Annual Meeting of Stockholders to a virtual-only format due to public health and safety concerns related to the coronavirus (COVID-19) pandemic.

  • Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year?
    Zacks

    Is Sangamo Therapeutics (SGMO) Stock Outpacing Its Medical Peers This Year?

    Is (SGMO) Outperforming Other Medical Stocks This Year?

  • Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast
    Business Wire

    Sangamo Therapeutics Announces First Quarter 2020 Conference Call and Webcast

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the Company has scheduled the release of its first quarter 2020 financial results after the market closes on Monday, May 11, 2020. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the Company will review its financial results and provide a business update.

  • Better Buy: Cara Therapeutics vs. Sangamo Therapeutics
    Motley Fool

    Better Buy: Cara Therapeutics vs. Sangamo Therapeutics

    Take Cara Therapeutics (NASDAQ: CARA) and Sangamo Therapeutics (NASDAQ: SGMO), for example. One thing that both Cara and Sangamo have in common, though, are promising pipeline candidates. Investors have placed a greater value on Sangamo's pipeline based on the company's higher market cap.

  • Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy
    Business Wire

    Sangamo Therapeutics Announces Presentations at 2020 Annual Meeting of the American Society of Gene & Cell Therapy

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the acceptance of several abstracts for presentation at the 23rd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) being held May 12th to May 15th, 2020, in a virtual format.

  • Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells
    Business Wire

    Mogrify and Sangamo announce collaboration and exclusive license agreement for Mogrify’s iPSC- and ESC-derived regulatory T cells

    Mogrify Ltd (Mogrify®), a UK company aiming to transform the development of cell therapies by the systematic discovery of novel cell conversions, and Sangamo Therapeutics (Sangamo) (Nasdaq: SGMO), a genomic medicine company, today announced that they have executed a collaboration and exclusive license agreement for Sangamo to develop allogeneic cell therapies from Mogrify’s proprietary induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) and Sangamo’s zinc finger protein (ZFP) gene-engineered chimeric antigen receptor regulatory T cell (CAR-Treg) technology.

  • How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Did Insiders Buy, In The Last Year?
    Simply Wall St.

    How Many Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Did Insiders Buy, In The Last Year?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer
    Business Wire

    Sangamo Appoints D. Mark McClung as Executive Vice President and Chief Business Officer

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of D. Mark McClung as Executive Vice President and Chief Business Officer. Mr. McClung will oversee commercial strategic planning, alliance management and corporate and business development.

  • Sangamo Announces Closing of Biogen Collaboration Agreement
    Business Wire

    Sangamo Announces Closing of Biogen Collaboration Agreement

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the closing of its previously announced sale of stock to Biogen Inc. (Nasdaq: BIIB) and that the global licensing collaboration agreement with Biogen for the development and commercialization of gene regulation therapies for Alzheimer’s, Parkinson’s, neuromuscular and other neurological diseases is now effective. Under the terms of the collaboration, Sangamo has received $225 million from the purchase by Biogen of newly issued Sangamo stock and will receive an upfront license fee of $125 million from Biogen no later than May 8, 2020. Additionally, Sangamo is eligible to earn up to $2.37 billion in other development, regulatory and commercial milestone payments, including up to $925 million in pre-approval milestone payments and up to $1.445 billion in first commercial sale and other sales-based milestone payments. Sangamo is also eligible to earn tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of products arising from the collaboration.

  • Sangamo Therapeutics Shows Promise
    TheStreet.com

    Sangamo Therapeutics Shows Promise

    For his first "Executive Decision" segment of Mad Money Friday night, Jim Cramer spoke with Sandy Macrae, president and CEO of Sangamo Therapeutics Inc. , a biotech company whose shares rose 4.9% after the company announced a new partnership with Biogen . Macrae explained that the partnership with Biogen allows Sangamo to perform early-stage research on a number of genes that Biogen is interested in and Biogen will then help to develop and commercialize the drugs that come from that research. Sangamo is currently working on treatments for both Alzheimer's and Parkinson's disease.

  • Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
    Business Wire

    Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences

    Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:

  • What A Biogen Deal Means For This Small Genetic Medicines Outlet
    Investor's Business Daily

    What A Biogen Deal Means For This Small Genetic Medicines Outlet

    Sangamo Therapeutics and Biogen are teaming up to develop several gene regulation therapies, the biotech companies said, sending SGMO stock flying on Friday.